These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
94 related articles for article (PubMed ID: 20562123)
1. Inhaled phosphodiesterase type 5 inhibitors restore chloride transport in cystic fibrosis mice. Lubamba B; Lebacq J; Reychler G; Marbaix E; Wallemacq P; Lebecque P; Leal T Eur Respir J; 2011 Jan; 37(1):72-8. PubMed ID: 20562123 [TBL] [Abstract][Full Text] [Related]
2. Preclinical evidence that sildenafil and vardenafil activate chloride transport in cystic fibrosis. Lubamba B; Lecourt H; Lebacq J; Lebecque P; De Jonge H; Wallemacq P; Leal T Am J Respir Crit Care Med; 2008 Mar; 177(5):506-15. PubMed ID: 18006891 [TBL] [Abstract][Full Text] [Related]
3. Correction of chloride transport and mislocalization of CFTR protein by vardenafil in the gastrointestinal tract of cystic fibrosis mice. Dhooghe B; Noël S; Bouzin C; Behets-Wydemans G; Leal T PLoS One; 2013; 8(10):e77314. PubMed ID: 24204804 [TBL] [Abstract][Full Text] [Related]
5. The effects of three phosphodiesterase type 5 inhibitors on ejaculation latency time in lifelong premature ejaculators: a double-blind laboratory setting study. Gökçe A; Halis F; Demirtas A; Ekmekcioglu O BJU Int; 2011 Apr; 107(8):1274-7. PubMed ID: 21929518 [TBL] [Abstract][Full Text] [Related]
6. Airway delivery of low-dose miglustat normalizes nasal potential difference in F508del cystic fibrosis mice. Lubamba B; Lebacq J; Lebecque P; Vanbever R; Leonard A; Wallemacq P; Leal T Am J Respir Crit Care Med; 2009 Jun; 179(11):1022-8. PubMed ID: 19299496 [TBL] [Abstract][Full Text] [Related]
7. Sildenafil (Viagra) corrects DeltaF508-CFTR location in nasal epithelial cells from patients with cystic fibrosis. Dormer RL; Harris CM; Clark Z; Pereira MM; Doull IJ; Norez C; Becq F; McPherson MA Thorax; 2005 Jan; 60(1):55-9. PubMed ID: 15618584 [TBL] [Abstract][Full Text] [Related]
8. Differences in hemodynamic and oxygenation responses to three different phosphodiesterase-5 inhibitors in patients with pulmonary arterial hypertension: a randomized prospective study. Ghofrani HA; Voswinckel R; Reichenberger F; Olschewski H; Haredza P; Karadaş B; Schermuly RT; Weissmann N; Seeger W; Grimminger F J Am Coll Cardiol; 2004 Oct; 44(7):1488-96. PubMed ID: 15464333 [TBL] [Abstract][Full Text] [Related]
9. Binding of tritiated sildenafil, tadalafil, or vardenafil to the phosphodiesterase-5 catalytic site displays potency, specificity, heterogeneity, and cGMP stimulation. Blount MA; Beasley A; Zoraghi R; Sekhar KR; Bessay EP; Francis SH; Corbin JD Mol Pharmacol; 2004 Jul; 66(1):144-52. PubMed ID: 15213306 [TBL] [Abstract][Full Text] [Related]
10. PDE5 Inhibitors as Potential Tools in the Treatment of Cystic Fibrosis. Noel S; Dhooghe B; Leal T Front Pharmacol; 2012; 3():167. PubMed ID: 23024633 [TBL] [Abstract][Full Text] [Related]
11. The in vivo effects of milrinone on the airways of cystic fibrosis mice and human subjects. Smith SN; Middleton PG; Chadwick S; Jaffe A; Bush KA; Rolleston S; Farley R; Delaney SJ; Wainwright B; Geddes DM; Alton EW Am J Respir Cell Mol Biol; 1999 Jan; 20(1):129-34. PubMed ID: 9870926 [TBL] [Abstract][Full Text] [Related]
12. Vardenafil reduces macrophage pro-inflammatory overresponses in cystic fibrosis through PDE5- and CFTR-dependent mechanisms. Noel S; Panin N; Beka M; Dhooghe B; Huaux F; Leal T Clin Sci (Lond); 2017 Jun; 131(11):1107-1121. PubMed ID: 28196856 [TBL] [Abstract][Full Text] [Related]
13. Classical activation of macrophages and vardenafil. Muimo R Clin Sci (Lond); 2017 Jun; 131(11):1141-1145. PubMed ID: 28533270 [TBL] [Abstract][Full Text] [Related]
14. Phosphodiesterase 5 inhibitors and cystic fibrosis: correcting chloride channel dysfunction. Clarke LL Am J Respir Crit Care Med; 2008 Mar; 177(5):469-70. PubMed ID: 18296466 [No Abstract] [Full Text] [Related]
15. Absence of clinically important HERG channel blockade by three compounds that inhibit phosphodiesterase 5--sildenafil, tadalafil, and vardenafil. Dustan Sarazan R; Crumb WJ; Beasley CM; Emmick JT; Ferguson KM; Strnat CA; Sausen PJ Eur J Pharmacol; 2004 Oct; 502(3):163-7. PubMed ID: 15476742 [TBL] [Abstract][Full Text] [Related]
16. Reduced expression of Tis7/IFRD1 protein in murine and human cystic fibrosis airway epithelial cell models homozygous for the F508del-CFTR mutation. Blanchard E; Marie S; Riffault L; Bonora M; Tabary O; Clement A; Jacquot J Biochem Biophys Res Commun; 2011 Aug; 411(3):471-6. PubMed ID: 21723850 [TBL] [Abstract][Full Text] [Related]
17. Base treatment corrects defects due to misfolding of mutant cystic fibrosis transmembrane conductance regulator. Namkung W; Kim KH; Lee MG Gastroenterology; 2005 Dec; 129(6):1979-90. PubMed ID: 16344066 [TBL] [Abstract][Full Text] [Related]
18. Phosphodiesterase 5 inhibitors for erectile dysfunction. Setter SM; Iltz JL; Fincham JE; Campbell RK; Baker DE Ann Pharmacother; 2005; 39(7-8):1286-95. PubMed ID: 15941818 [TBL] [Abstract][Full Text] [Related]
19. The CF-CIRC study: a French collaborative study to assess the accuracy of cystic fibrosis diagnosis in neonatal screening. Sermet-Gaudelus I; Roussel D; Bui S; Deneuville E; Huet F; Reix P; Bellon G; Lenoir G; Edelman A BMC Pediatr; 2006 Oct; 6():25. PubMed ID: 17018149 [TBL] [Abstract][Full Text] [Related]
20. Expression of delta F508 cystic fibrosis transmembrane conductance regulator protein and related chloride transport properties in the gallbladder epithelium from cystic fibrosis patients. Dray-Charier N; Paul A; Scoazec JY; Veissière D; Mergey M; Capeau J; Soubrane O; Housset C Hepatology; 1999 Jun; 29(6):1624-34. PubMed ID: 10347100 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]